Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 4, 2006, Pages 397-420

  Michiels, Jan Jacques ^a,c   Berneman, Zwi ^a   Gadisseur, Alain ^a   Van Der Planken, Marc ^a   Schroyens, Wilfried ^a   Van De Velde, Ann ^a   Van Vliet, Huub ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Goodheart Institute   (Netherlands)

Author keywords

Bleeding time; DDAW; Factor VIII:C; Ristocetin cofactor activity; Von Willebrand collagen binding activity; Von Willebrand disease; Von Willebrand factor

Indexed keywords

AGAROSE; COLLAGEN; POLYMER; RISTOCETIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AUTOSOMAL DOMINANT DISORDER; BLEEDING TIME; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOELECTROPHORESIS; MALE; MOLECULAR WEIGHT; OLIGOMERIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 2A; VON WILLEBRAND DISEASE TYPE 2B; VON WILLEBRAND DISEASE TYPE 2C; VON WILLEBRAND DISEASE TYPE 2D; VON WILLEBRAND DISEASE TYPE 2E; VON WILLEBRAND DISEASE TYPE 2M; VON WILLEBRAND DISEASE TYPE 2N; VON WILLEBRAND DISEASE TYPE 2U;

ANTIGENS; BLEEDING TIME; FACTOR VIII; GENES, DOMINANT; GENES, RECESSIVE; HUMANS; PLATELET AGGREGATION; VARIATION (GENETICS); VON WILLEBRAND DISEASE;

EID: 33748513840     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606293422     Document Type: Review

References (77)

1. Goodeve A, Peake I. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. Baillieres Clin Haematol 2001;14:235.
2. De Wit TR, Van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: Biological implications. Baillieres Clin Haematol 2001;14:241.
3. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Baillieres Clin Haematol 2001;14:257.
4. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520.
5. Zimmerman ThS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. J Clin Invest 1986;77:947.
6. Schneppenheim R, Budde U, Ruggeri ZM. A molecular approach to the classification of von Willebrand disease. Baillieres Clin Haematol 2001;14:281.
7. Michiels JJ, Van De Velde A, Van Vliet HHDM, et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: Diagnostic and therapeutic implications. Semin Thromb Hemost 2002;28:111.
8. Zhang Z, Lindstedt M, Blombäck M, Anvret M. Effects of mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995;96:388.
9. Eikenboom JCJ, Reitsma PH, Peerlinck KJM, Briët E. Recessive inheritance of von Willebrand's disease. Lancet 1993;341:982.
10. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med 1941;26:1812.
11. Sramek R, Sramek A, Koster T, et al. A randomized and blinded comparison of 3 bleeding time techniques - The Ivy, and the Simplate II in 2 directions. Thromb Haemost 1992;67:357.
12. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1984;28:1356.
13. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002;28:173.
14. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand factor antigen to collagen. Thromb Res 1986;43:303.
15. Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: A 15-year journey. Semin Thromb Hemost 2002;28:191.
16. Hubbard AR, Sands D, Chang AC, Mazurier C. Standardization of von Willebrand factor in therapeutic concentrates: Calibration of the 1st International Standard for von Willebrand factor concentrate (00/514). Thromb Haemost 2002;88:380.
17. Favaloro EJ, Smith J, Petinos P, et al. Laboratory testing for von Willebrand's disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999;82:1276.
18. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA) detection of von Willebrand disease (VWD) and discrimination of VWD subtypes depends on collagen source. Thromb Haemost 2000;83:127.
19. Favaloro EJ, Bukuya M, Martinelli T, et al. A comparative multi-laboratory assessment of three factor/von Willebrand factor concentrates. Thromb Haemost 2002;87:466.
20. Neugebauer BM, Goy C, Budek I, Setitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium and high multimers of von Willebrand factor. Semin Thromb Hemost 2002;28:139.
21. Mazurier C, Meyer D. Factor VIII binding of von Willebrand factor and the diagnosis of type 2N von Willebrand disease. Thromb Haemost 1996;76:270.
22. Brosstad F, Kjonniksen I, Ronning B, Stromorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986;55:276.
23. Eikenboom JCJ, Castaman G, Kamphuisen PW, et al. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002;87:252.
24. Peake IA, Bloom AL, Giddings JC. Inherited variants of FVIII-VIII-related protein in von Willebrand's disease. N Engl J Med 1974;291:113.
25. Green D, Philip KJ. Variant von Willebrand's disease. Thromb Haemost 1980;43:2.
26. Hill FGH, Enayat MS, George AJ. Investigation including VIIIR:AG multimeric analysis of a large kindred with type IIA von Willebrand's disease showing a dominant inheritance and similar gene expression in four generations. Thromb Haemost 1983;50:735.
27. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980;302:1047.
28. Nichols W, Ginsburg D. Von Willebrand disease. Medicine 1997;76:1.
29. Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. Thromb Haemost 1997;78:451.
30. Meyer D, Fressinaud E, Hilbert L, et al. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Baillieres Clin Haematol 2001;14:349.
31. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003;88:94.
32. Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992;267:4424.
33. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004;103:2032.
34. Batlle J, Lopez-Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand's disease. Blood 1986;68:1207.
35. Batlle J, Lassieri J, Villamor AF, et al. Proteolytic rocessing of von Willebrand factor subunit: Heterogeneity in type IIA von Willebrand disease. Ann Hematol 1994;68:111.
36. Holmberg L, Berntopr E, Donner M, Noilsson IM. Von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986;68:668.
37. Weiss HJ, Sussman I. A new von Willebrand variant (type 1, New York): Increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986;68:149.
38. Firkin B, Firkin F, Stott L. Von Willebrand's disease type B: A newly defined bleeding diathesis. Aust N Z Med 1973;3:225.
39. Howard MA, Salem HH, Thomas KB, et al. Variant von Willebrand's disease type B - Revisited. Blood 1982;60:1420.
40. Raboniwitz I, Tuley EA, Mancuso DJ, et al. Von Willebrand disease type B: A missence mutation selectively abolishes ristocetine-induced von Willebrand binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 1992;89:9846.
41. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160.
42. Mannucci PM, Lombardi R, Bader R, et al. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with abnormal von Willebrand factor. Blood 1985;66:796.
43. Federici AB, Canciani MT, Forza I, et al. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease. Thromb Haemost 2000;84:1127.
44. Hoyer LW, Rizza CR, Tuddenham GD, et al. Von Willebrand factor multimer patterns in von Willebrand's disease. Br J Haematol 1983;55:493.
45. Mancusco DJ, Kroner PhA, Christopherson PM, et al. Type 2M:Milwaukee-1 von Willebrand disease with an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor Al domain causes deficient binding of von Willebrand to platelets. Blood 1996;88:2559.
46. Hillery CA, Mabcusco DJ, Sadler JE, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin - but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998;91:1572.
47. Hilbert L, Jenkins PV, Gaucher G, et al. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb Haemost 2000;84:188.
48. Nitu-Whalley IC, Ridell A, Lee C, et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: A reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000;84:998.
49. Lethagen S, Frick K, Isaksson C, et al. Revised classification and treatment of von Willebrand disease. Thromb Haemost 1998;80:199.
50. 611 Ø His) in type I "platelet discordant" von Willebrand disease with desopressine-induced thrombocytopenia. Br J Haematol 1995;89:656.
51. Hilbert L, Gaucher C, Mazurier C. Idenfication of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (VWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of VWF. Blood 1995;86:1010.
52. Nishikubo T, Christophe O, Lavergne J-M, et al. Abnormal proteolytic processing of von Willebrand factor Arg611Cys and Arg611His. Thromb Haemost 1997;77:174.
53. Ribba AS, Hilbert L, Lavergne JM, et al. The Arg552Cys (R552C) mutation within the A1 loop of von Willebrand factor (VWF) induces abnormal folding with loss-of-function resulting in 2A-like phenotype of von Willebrand disease. Study of ten patients and of mutated recombinant VWF. Blood 2001;97:952.
54. Ruggeri ZA, Nilsson IM, Lombardi R, et al. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest 1982;70:1124.
55. Holmberg L, Karpman D, Isakson C, et al. Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease. Thromb Haemost 1998;79:718.
56. Mazurier C, Manucci PM, Parquet-Gernez A, et al. Investigation of a case of subtype IIC von Willebrand disease: Characterization of the variability of this subtype. Am J Hematol 1986;22:301.
57. Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994;84:1024.
58. Battle J, Lopez-Fernandez MF, Lasiera J, et al. Von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibship. Am J Hematol 1986;21:177.
59. Battle J, Lopez Gernandez MF, FernandezVillamor A, et al. Multimeric pattern discrepancy between platelet and plasma von Willebrand factor in type IIC von Willebrand disease. Am J Hematol 1986;22:87.
60. Schneppenheim R, Thomas KB, Krey S, et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995;95:681.
61. Mannucci PM, Lombardi R, Pareti FI, et al. A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers. Blood 1983;62:1000.
62. Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984;63:1369.
63. Schneppenheim R, Brassard J, Krey S, et al. Defective dimerization of von Willebrand factor subunits due to a Cys Ø Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996;93:3581.
64. Schneppenheim R, Budde U, Obser T, et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001;97:2059.
65. Balloid P, Gaucher C, Affolter B, et al. New variant of type II von Willebrand's disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding history. Am J Hematol 1995;49:21.
66. Gaucher C, Parquet A, Baillod P, et al. Mutations in the D3 domain of von Willebrand factor are identified in patients classified as 1 or 2A von Willebrand disease. Thromb Haemost 1997(suppl):388 (abstract OC-1583).
67. Castaman G, Rodeghiero F, Lattuada A, Mannucci PM. A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. Thromb Res 1992;65:343.
68. Ledford M, Rabinowitz I, Sadler JE, et al. Newriant of von Willebrand disease type II with markedly increased levels of von Willebrand antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood 1993;82:169.
69. Mannucci PM, Lombardi R, Federici AB, et al. A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF). Blood 1986;68:269.
70. Gralnick HR, Williams SB, McKeown LP, et al. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure. Am J Hematol 1987;24:259.
71. Federici AB, Manuccio PM, Lombardi R, et al. Type II H von Willebrand disease: New structural abnormality of plasma and platelet von Wilebrand factor in a patients with prolonged bleeding time and borderline levels of ristocetin cofactor activity. Am J Hematol 1989;32:287.
72. Lopez-Fernandez MF, Gonzalez-Boullousa R, Blanco-Lopez MJ, et al. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (1D). Am J Hematol 1991;36:163.
73. Ciavarelli G, Ciavarelli N, Antoncecchi S, et al. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC). Blood 1985;66:1423.
74. Mazurier C. Von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992;67:391.
75. Mazurier C, Goudemand J, Hubert L, et al. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology. Laboratory diagnosis and molecular biology. Baillieres Clin Haematol 2001;14:337.
76. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996;76:598.
77. Mazurier C, Gaucher C, Joriuex S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ("Normandy") von Willebrand disease. Br J Haematol 1994;88:849.